Cancer Immunotherapy Side Effects Differ Sharply Across Racial Groups, Massive Data Analysis Reveals
An analysis of nearly half a million clinical trials and real-world data from over 91,000 patients reveals that immune-related side ...
An analysis of nearly half a million clinical trials and real-world data from over 91,000 patients reveals that immune-related side ...
A real-world study of 95 patients in Tokyo confirms that pembrolizumab combined with chemotherapy before and after surgery delivers event-free ...
A genomic study of 841 melanoma patients at NYU Langone Health found that underrepresented minority patients experienced significantly more immune ...
A new meta-analysis of five observational studies finds that adding pembrolizumab to neoadjuvant chemotherapy in early-stage triple-negative breast cancer appears ...
A Japanese case report describes more than three years of progression-free survival in pulmonary tumour thrombotic microangiopathy after prompt nivolumab ...
A single cycle of atezolizumab plus tiragolumab triggered simultaneous myocarditis, hepatitis, thrombocytopenia, and dermatomyositis in a lung cancer patient, whose ...
A new case report describes how the immunotherapy drug pembrolizumab triggered pemphigoid nodularis, a rare blistering skin disease that initially ...
A new review explains how gut microbes program immunosuppressive regulatory B cells through cytokine and metabolite signals, with major implications ...
A retrospective review of 35 published cases shows that nivolumab can trigger cytokine release syndrome weeks to months into treatment, ...
A pharmacovigilance analysis of US and Japanese adverse event databases finds that PD-1 and PD-L1 checkpoint inhibitors show a robust, ...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine